Veterans asking their VA provider about GLP-1 medications for weight loss often discover that coverage depends entirely on what diagnosis appears in their medical record, not simply on having obesity. Ozempic and Wegovy contain identical active ingredients, as do Mounjaro and Zepbound, yet the Department of Veterans Affairs treats them as categorically different drugs with separate coverage pathways. Understanding these distinctions before an appointment is critical for veterans seeking access to these medications.

Why Do Identical Drugs Have Different VA Coverage?

The confusion stems from how the FDA approves medications. Semaglutide is the active ingredient in both Ozempic and Wegovy, both made by Novo Nordisk. Ozempic received FDA approval for Type 2 diabetes management, while Wegovy was approved for chronic weight management and, following a 2023 trial, for reducing major cardiovascular events in patients with established heart disease and obesity. Same molecule, different doses, different FDA approvals, completely different VA coverage pathways.

The same pattern applies to tirzepatide, the active ingredient in both Mounjaro and Zepbound, both made by Eli Lilly. Mounjaro is FDA-approved for Type 2 diabetes, while Zepbound is approved for obesity and separately for moderate to severe obstructive sleep apnea. The VA's formulary guidance reflects these distinctions, meaning a veteran's access to any of these medications hinges on their documented medical diagnosis.

What Diagnoses Actually Qualify for VA Coverage?

The VA covers these drugs through its Meds by Mail program and at VA pharmacies, but the diagnosis in a veteran's medical record is the determining factor. Based on the VA's current formulary guidance as of mid-2026, coverage breaks down by specific diagnosis:

• Type 2 Diabetes: Veterans with a Type 2 diabetes diagnosis can access Ozempic and Mounjaro through the VA formulary.
• Obstructive Sleep Apnea: Veterans with an obstructive sleep apnea diagnosis can access Zepbound, which is FDA-approved for this condition.
• Cardiovascular Disease Prevention: Veterans with a diagnosis for the prevention of major adverse cardiovascular events (MACE), meaning established heart disease with obesity, can access Wegovy.
• Weight Loss Alone: Veterans who want these drugs for weight loss without one of those specific diagnoses face a significantly harder path, as the VA classifies obesity medications as non-formulary except for documented medical necessity, and approval rates for weight-loss-only indications are low.

CHAMPVA, the Civilian Health and Medical Program of the Department of Veterans Affairs, covers dependents of 100 percent permanently and totally disabled veterans. However, CHAMPVA does not cover GLP-1 medications for weight loss at all. It covers Ozempic and Mounjaro for Type 2 diabetes, Zepbound for sleep apnea, and Wegovy only for MACE prevention, following the same diagnosis-driven structure as the VA but with no weight-loss pathway under any circumstances.

How Do Tricare and Medicare Compare to VA Coverage?

Tricare, the health insurance program for active-duty service members, retirees, and their families, is more permissive than the VA for weight-loss indications. Tricare Prime, Select, and premium-based plans cover Wegovy, Saxenda, and Zepbound for weight management with prior authorization, provided the member meets specific body mass index (BMI) criteria and other requirements.

To qualify for Tricare weight-loss GLP-1 coverage, members must meet these conditions:

• BMI Threshold: A BMI of 30 or above, or 27 or above if the member has a weight-related comorbidity such as high blood pressure or type 2 diabetes.
• Lifestyle Modification Attempt: The member must have attempted lifestyle modification for at least six months before requesting medication.
• Prior Oral Medication Trial: The member must have tried an oral weight-loss medication without success before accessing GLP-1 drugs.

However, Tricare For Life and direct-care-only beneficiaries are excluded from weight-loss GLP-1 coverage as of August 31, 2025. Meanwhile, Medicare introduced its Medicare GLP-1 Bridge program, which offers these medications for $50 per month, providing an alternative pathway for eligible beneficiaries.

Steps to Navigate VA Coverage for Weight-Loss Medications

Veterans seeking GLP-1 medications should take specific steps before meeting with their VA provider to maximize their chances of approval:

• Review Your Active Diagnoses: Log into MyHealtheVet and check your VA health record for active diagnoses including Type 2 diabetes, cardiovascular disease, or obstructive sleep apnea. If any of these diagnoses are present, the coverage pathway is clearer and the conversation with your provider becomes simpler.
• Enroll in MOVE! Program: Veterans who want these medications for weight management without a qualifying diagnosis should ask their provider about enrollment in the VA's MOVE! weight management program. Documented participation in this structured lifestyle intervention strengthens the case for pharmacological treatment and is often a prerequisite in the VA's prior authorization process for weight-loss indications. The MOVE! program is free and available at all VA medical centers.
• Contact the VA Pharmacy Benefits Line: Veterans with questions about their specific formulary coverage can call the VA pharmacy benefits line at 888-385-0235 or check the VA National Formulary at va.gov/formularyadvisor to confirm what medications they qualify for based on their diagnoses.

The most productive thing a veteran can do before discussing GLP-1 medications with their VA provider is to understand their own medical record and which diagnoses might qualify them for coverage. This preparation transforms what could be a frustrating conversation into a straightforward discussion about treatment options.